Update on fluoropyrimidine treatments and mandatory screening for DPD deficiency

News Healthcare & Pharma Guidance

Date: 5th Nov, 2024 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

On "05/11/2024", the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding "Update on fluoropyrimidine treatments and mandatory screening for DPD deficiency". The updated guidance emphasizes the importance of conducting regular screenings for dihydropyrimidine dehydrogenase (DPD) deficiency in patients undergoing fluoropyrimidine treatment, particularly those with a partial deficiency. Due to severe toxicity risks, these screenings are crucial in preventing adverse effects.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Update on fluoropyrimidine treatments and mandatory screening for DPD deficiency

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Update on fluoropyrimidine treatments and mandatory screening for DPD deficiency

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.